Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...
The Scientist8h
Ribosomes Team Up to Translate Tricky mRNA Segments
During translation, ribosomes can pause on the nucleic acid. Researchers showed that collisions from incoming proteins get ...
JD Supra24d
Some AI-Discovered Drugs Carry More IP Risks Than Others - Here's Why
A polypeptide’s potential variations are virtually ... but which may also confer weaker IP rights. Small molecule drugs carry less IP risk when using AI tools in screening.
Medical Xpress1mon
Genetically altered fat cells in mice show promise for obesity treatment
Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic polypeptide ... to burn extra ATP—a molecule used for energy—without ...
Frontiers2y
An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis
Attempts to design small molecule therapies directed to this cytokine have not led to approved products yet. Here we report the discovery and development of a potent small molecule inhibitor of TNF ...
Pharmaceutical Technology8y
Lonza to Divest Peptides Business and Operations to PolyPeptide Basel
Lonza and the PolyPeptide Group have jointly announced that PolyPeptide Laboratories Holding (PPL) has entered into a definitive agreement ...